26 related articles for article (PubMed ID: 20636367)
1. Population attributable fractions and joint effects of key risk factors for multiple sclerosis.
van der Mei I; Lucas RM; Taylor BV; Valery PC; Dwyer T; Kilpatrick TJ; Pender MP; Williams D; Chapman C; Otahal P; Ponsonby AL
Mult Scler; 2016 Apr; 22(4):461-9. PubMed ID: 26199349
[TBL] [Abstract][Full Text] [Related]
2. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
3. Antiviral immune response in patients with multiple sclerosis, healthy siblings and twins.
Ristori G; Mechelli R; Anderson J; Mengoni F; Sauzullo I; Annibali V; Cannoni S; Aloisi F; James JA; Salvetti M
Mult Scler; 2010 Dec; 16(12):1527-8. PubMed ID: 20798134
[No Abstract] [Full Text] [Related]
4. Assessment of Epstein-Barr virus (EBV) serostatus by enzyme immunoassays: plausibility of the isolated EBNA-1 IgG positive serological profile.
García T; Tormo N; Gimeno C; Navarro D
J Infect; 2008 Oct; 57(4):351-3. PubMed ID: 18789535
[No Abstract] [Full Text] [Related]
5. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
6. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
7. The association between anti-EBNA-1 IgG and multiple sclerosis clinical disease activity.
Bahreini SA; Zahednasab H; Saadatnia M; Jabalameli MR
Eur J Neurol; 2010 Oct; 17(10):e95; author reply e96. PubMed ID: 20636367
[No Abstract] [Full Text] [Related]
8. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis.
Almohmeed YH; Avenell A; Aucott L; Vickers MA
PLoS One; 2013; 8(4):e61110. PubMed ID: 23585874
[TBL] [Abstract][Full Text] [Related]
9. Epstein-barr virus: environmental trigger of multiple sclerosis?
Lünemann JD; Kamradt T; Martin R; Münz C
J Virol; 2007 Jul; 81(13):6777-84. PubMed ID: 17459939
[No Abstract] [Full Text] [Related]
10. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology.
Bauer G
Clin Lab; 2001; 47(5-6):223-30. PubMed ID: 11405600
[TBL] [Abstract][Full Text] [Related]
11. [Multiple sclerosis and Epstein-Barr virus : new developments and perspectives].
Ruprecht K
Nervenarzt; 2008 Apr; 79(4):399-407. PubMed ID: 17713752
[TBL] [Abstract][Full Text] [Related]
12. Progress in recent research on multiple sclerosis.
Davison AN
Biochem Soc Trans; 1978; 6(2):443-7. PubMed ID: 348529
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
